Zevra Therapeutics (ZVRA) Income towards Parent Company (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Income towards Parent Company of $37.9 million for Q1 2026, up 211.47% on a QoQ basis from $12.2 million in Q4 2025, and up 1322.65% year-over-year from $2.7 million in Q1 2025.
Zevra Therapeutics (ZVRA) Income towards Parent Company (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Income towards Parent Company history runs 13 years deep, the most recent figure standing at $37.9 million for Q1 2026.
- Quarterly Income towards Parent Company rose 1322.65% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.2 million (up 235.04% YoY) and the FY2025 annual result came in at $83.2 million, up 178.88% from the prior year.
- Income towards Parent Company was $37.9 million for Q1 2026 at Zevra Therapeutics, up from $12.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $74.7 million in Q2 2025 and bottomed at -$35.7 million in Q4 2024.
- A 5-year average of -$3.0 million and a median of -$5.7 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company sank 674.39% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Income towards Parent Company stood at -$3.0 million in 2022, then slumped by 569.31% to -$19.9 million in 2023, then plunged by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025, then soared by 211.47% to $37.9 million in 2026.
- Business Quant data shows ZVRA's Income towards Parent Company at $37.9 million in Q1 2026, $12.2 million in Q4 2025, and -$544000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -13.22 Mn |
| Dec 31, 2022 | -2.97 Mn |
| Sep 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -21.97 Mn |
| Mar 31, 2022 | 10.49 Mn |
| Dec 31, 2021 | -2.70 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | 6.20 Mn |